Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned between Allied Minds and Bristol-Myers Squibb Company, has entered into a worldwide licensing agreement with Yale University for a proprietary platform technology and associated lead molecules that will be further developed to treat diseases such as prostate cancer.

Developed by Professor David A. Spiegel, Ph.D., M.D. and his team at Yale University, the proprietary synthetic molecules, known as Antibody Recruiting Molecules (ARMs), work by harnessing the power of the body’s own immune system to treat cancer.